8-K: Curaleaf Seeks to Halt Aurora Share Issuance

Curaleaf Holdings, Inc. has applied to the Alberta Securities Commission to halt Aurora's share issuance program, alleging it's an abusive defensive tactic diluting shareholders during Curaleaf's pending offer.

Summary

• Curaleaf Holdings, Inc. has filed an application with the Alberta Securities Commission (ASC) to stop Aurora from issuing shares under its at-the-market (ATM) program.
• Curaleaf alleges that Aurora's ATM program is an improper and abusive defensive tactic that dilutes existing Aurora shareholders and increases the cost of Curaleaf's offer.
• The application requests an expedited hearing before the ASC.
• Curaleaf states that Aurora's share issuances have diluted Aurora shareholders by approximately 10.8% since February 2026 and by about 4.9% since June 2026.
• These issuances have increased the aggregate value required to complete Curaleaf's offer by over US$11 million.
• Curaleaf argues that Aurora's continued share issuance is inconsistent with its stated position of having ample cash and an industry-leading balance sheet.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the aggressive legal action and potential for protracted disputes, which introduces uncertainty and risk.

Positives

• Curaleaf is taking proactive steps to protect shareholder value and ensure a fair consideration of its offer.
• The application aims to prevent further dilution of Aurora shareholders.
• Curaleaf is seeking an expedited hearing, indicating a desire for swift resolution.

Negatives

• The filing indicates a contentious dispute between Curaleaf and Aurora, potentially leading to prolonged legal battles.
• Aurora's alleged actions are seen as dilutive to its shareholders, reducing their ownership stake and the value of Curaleaf's offer.
• The increased cost of Curaleaf's offer due to Aurora's share issuances is a negative financial impact.

Risks

• The outcome of the ASC application is uncertain and could impact the progress and terms of Curaleaf's offer.
• Protracted legal proceedings could create significant distraction and consume resources for both companies.
• The dispute may negatively affect investor sentiment towards both Curaleaf and Aurora.
• There is a risk that Aurora shareholders may not be able to fairly consider and respond to Curaleaf's offer due to ongoing share issuances.

Future Outlook

Curaleaf is focused on providing Aurora shareholders with a compelling opportunity to realize significant value. The company is seeking an expedited hearing from the ASC to halt Aurora's share issuance program.

Management Comments

• "Every Share Aurora sells below the Offer price raises the same question: if management believes US$4.00 undervalues the company and the company has ample cash, why continue diluting its shareholders? These issuances erode shareholder ownership value, increase the cost of the Offer, and make it harder for shareholders to decide their own future. They seem solely designed to protect management's position, at the expense of investors," said Boris Jordan, Chairman and Chief Executive Officer of Curaleaf.
• "Today, we are taking action to protect Aurora shareholders from ongoing dilution by asking the Alberta Securities Commission to stop Aurora from continuing this abusive practice. Aurora shareholders deserve the freedom to decide whether to accept the Offer without Aurora management creating obstacles that limit their choice and value," concluded Mr. Jordan.

Industry Context

StockSavvy.ai notes that aggressive defensive tactics, such as share issuances to dilute an acquirer's offer, are not uncommon in M&A situations, particularly in rapidly evolving industries like cannabis. However, regulatory intervention by bodies like the ASC can significantly alter the landscape of such disputes.

Legal Proceedings

• Curaleaf Holdings, Inc. has filed an application with the Alberta Securities Commission to halt Aurora's at-the-market share issuance program.
• Curaleaf alleges that Aurora's use of the ATM program is an improper and abusive defensive tactic.

Stakeholder Impact

• Aurora shareholders: Face dilution of their ownership stake and potential reduction in the value of Curaleaf's offer.
• Curaleaf shareholders: May face increased costs for the acquisition and potential delays or complications in the transaction.
• Aurora management: Accused by Curaleaf of using the ATM program to protect their positions at the expense of investors.

Next Steps

• Curaleaf has requested an expedited hearing before the Alberta Securities Commission.
• The ASC will review Curaleaf's application to halt Aurora's ATM program.
• Aurora shareholders are encouraged to read the Offer documents carefully and in their entirety.

Key Dates

Recommendation

The situation is highly contentious with legal action underway. While Curaleaf is acting to protect its offer and shareholder value, the dispute introduces significant uncertainty. Investors should hold positions until the regulatory outcome and the future of the offer become clearer.

Keywords

share issuance, Alberta Securities Commission, dilution, takeover offer, defensive tactic, at-the-market program, shareholder value, cannabis industry